Back to Pipeline

Veliparib

Veliparib (ABT-888) is a PARP inhibitor being investigated to treat non-small cell lung cancer, BRCA breast cancer and ovarian cancer.

Type of Molecule

Small Molecule

Target

PARP

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Ovarian Cancer n/a
Phase 3
Breast Cancer n/a
Phase 3
Lung Cancer n/a
Phase 3